Allergic bronchopulmonary aspergillosis (ABPA) is a fungal infection of the lung due to a hypersensitivity reaction to antigens of Aspergillus fumigatus after colonization into the airways. It characteristically presents with bronchospasm, pulmonary infiltrates, eosinophilia, and immunologic evidence of allergy to the antigens of Aspergillus species.
An infection by Aspergillus species causes a broad spectrum of illnesses in humans and depends on the immune status of the host.
Aspergillus species are a common causative organism for fungal infection in immunocompromised individuals.
Allergic bronchopulmonary aspergillosis commonly presents in the third to fifth decade of life. It is also common in children. It usually found in severe asthmatics and patients with cystic fibrosis.
A. fumigatus is the most common organism that causes ABPA, and the fungus requires dead organic matter to survive. The highest incidence of the infection is known to be in the winter season around the world (secondary to fallen leaves).
Genetic association: HLA-DR molecules DR2, DR5, and possibly DR4 or DR7 contribute to susceptibility; whereas, HLA-DQ2 contributes to resistance and a combination of these may determine the outcome of ABPA in CF and asthma.
The pathogenesis of allergic bronchopulmonary aspergillosis remains incompletely understood. A. fumigatus spores that get inhaled in sufficient quantities behave as allergens. Normally a low level of IgG against fungal antigens in the circulation and the low antifungal secretory IgA in bronchoalveolar fluid suggest that healthy individuals can effectively eliminate fungal spores. In contrast, exposure of atopic individuals to fungal spores or mycelial fragments results in the formation of IgE and IgG antibodies.
Th2 cells (Helper T cells) play an essential role in the hypersensitivity reaction caused by the A. fumigatus antigen. It manifests as IgE production, eosinophilia, mast cell degranulation, and bronchiectasis.
A. fumigatus proteases release proinflammatory cytokines, such as IL-8 which causes epithelial cell damage and disruption of protective barriers which triggers the hypersensitivity reaction. It also releases cytokines interleukin (IL)-4, IL-5, and IL-13, which increases blood and airway eosinophils as well as IgE.
Histopathologically, there is chronic bronchial inflammation, eosinophilia (leading to the development of an area of parenchymal scarring), airway remodeling, and bronchiectasis. Bronchi may show impacted mucus plug containing fungal hyphae, fibrin, Charcot-Leyden crystals, Curschmann spirals. The dichotomous branching of hyphae occurs at 45-degree angles.
Allergic bronchopulmonary aspergillosis occurs primarily in patients with asthma or cystic fibrosis.
On physical examination:
There is no individual test that establishes the diagnosis of allergic bronchopulmonary aspergillosis. The diagnosis is based on classic clinical manifestations, radiographic findings, and immunological findings.
Aspergillus skin test:
Radiological manifestations of ABPA:
The following shadows may present radiologically:
Revised radiologic classification of allergic bronchopulmonary aspergillosis based on findings on a high-resolution computed tomography of the chest.
Pulmonary function tests:
Bronchoscopy: Mucoid impaction may be evident, and bronchial brushings may reveal mucus that contains aggregates of eosinophils, fungal hyphae, and eosinophil-derived Charcot–Leyden crystals. The finding of hyphae-filled mucus plugs is considered pathognomonic for ABPA. BAL fluid analysis from patients with ABPA: moderate eosinophilia (especially in steroid-naive patients) and increased levels of Aspergillus-specific IgE and IgA, but not IgG.
Sputum cultures for A. fumigatus: It is not diagnostic, but if it reveals an organism, then it helps in drug susceptibility test.
Following criteria are used for diagnosis and typing of ABPA.
1) Rosenberg-Patterson criteria: It has five major and three minor criteria.
2) Criteria proposed by ISHAM working group :
The main aim of treatment of allergic bronchopulmonary aspergillosis is to control episodes of acute inflammation and to limit progressive lung injury.
Goals of treatment:
• Controlling symptoms • Preventing exacerbations • Preserving normal lung function
Drugs used for the treatment of ABPA:
Corticosteroids: Systemic corticosteroids are the primary therapy for ABPA. A steroid helps to relieve the symptoms and decreases airflow obstruction, decreases serum IgE and reduces peripheral blood eosinophils. Moreover, there is a resolution of pulmonary inflammation, pulmonary infiltrates, and it prevents irreversible lung damage.
Oral antifungal agents: Antifungal agents act by decreasing the fungal load that reduces inflammatory activity and act as steroid-sparing agents. Antifungal therapy may help to decrease exacerbations.
Antibiotics: To prevent or treat an associated secondary bacterial infection.
Omalizumab: An anti-IgE recombinant humanized monoclonal antibody which prevents binding of IgE to Fc-epsilon RI receptor on mast cells and basophils.
Differential Diagnosis of allergic bronchopulmonary aspergillosis:
Itraconazole interferes with the hepatic metabolism of several medications, including cyclosporine, oral hypoglycemics, tacrolimus, terfenadine, cisapride, and midazolam. Impaired absorption is most significant with proton pump inhibitors.
Glucocorticoids side effects: Weight gain, osteopenia, acne, skin atrophy, diabetes mellitus, glaucoma, cataracts, avascular necrosis of bone, infection, hypertension, and growth retardation in children.
Omalizumab side effects: The most common reaction is swelling and redness at the injection site. Anaphylaxis may occur in asthmatics.
New Proposed clinical staging of allergic bronchopulmonary aspergillosis in asthmatic patients:
Stage 0: Asymptomatic
Stage 1: Acute
Stage 2: Response
Stage 3: Exacerbation
Stage 4: Remission
Sustained clinical-radiological improvement and
Stage 5a: Treatment-dependent ABPA
Stage 5b: Glucocorticoid-dependent asthma
Stage 6: Advanced ABPA
EPR-3: third expert panel report; GINA: global initiative against asthma
The natural history, progression, remission, and recurrences of ABPA are not well understood. Patients without central bronchiectasis at the time of diagnosis tend to maintain their lung function despite occasional exacerbations.
With appropriate treatment, long-term control of ABPA is feasible, and durable remissions are common.
Treatment of Stage 1 disease using corticosteroids typically results in decreased sputum production, improved control of bronchospasm, over 35% reduction in total IgE within 8 weeks, clearing of precipitating antibodies, and resolution of radiographic infiltrates. IgE levels typically do not completely normalize, but it decreases by approximately one-half of peak levels seen in the acute stage.
Progression of Stage 5 disease to pulmonary fibrosis may be preventable if patients maintain therapy on low-dose steroids.
Persons with an FEV1 persistently under 0.8 L have a worse prognosis.
Patients with allergic bronchopulmonary aspergillosis have to be more conscious about the worsening of their symptoms. If worsening of respiratory symptoms occurs on treatment or new respiratory symptoms develops on stage 2 and stage 3, then immediately consult a pulmonologist.
Patients with ABPA-CB have a higher chance to get a secondary infection and complications related to bronchiectasis. If fever or hemoptysis occurs, then immediately consult a pulmonologist.
If a patient is receiving long-term oral corticosteroids, all adverse drug effects should be properly understood. Screening should be performed for corticosteroid adverse effects of osteoporosis/osteopenia (by bone density measurement) and cataracts (by eye exams) regularly.
Patients bronchiectasis should receive training on sputum clearance techniques. Recommendations are for influenza and pneumococcal immunizations.
Avoid areas and environmental conditions with high mold counts, such as decomposing organic materials, and moldy indoor environments.
Allergic bronchopulmonary aspergillosis is a fungal infection of the lung secondary to a hypersensitivity reaction to antigens of Aspergillus fumigatus. This disease process is uncommon; however, routine screening is necessary for asthmatic and cystic fibrosis patients. The interprofessional approach of pulmonologists, infectious diseases, primary care physicians, pharmacists, and other healthcare professionals is essential to educate and improve patient outcomes. [Level V] A focused history and physical examination along with appropriate imaging with a high-resolution chest tomography of the chest are critical to establish an early diagnosis and initiate early treatment to prevent the development of bronchiectasis or pulmonary fibrosis. As targeted immunotherapy is evolving, there may be new treatment options in the near future.
We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.
This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.
Click Your Answer Below
Would you like to access teaching points and more information on this topic?
Click Your Answer Below
Would you like to access teaching points and more information on this topic?
|Oguma T,Taniguchi M,Shimoda T,Kamei K,Matsuse H,Hebisawa A,Takayanagi N,Konno S,Fukunaga K,Harada K,Tanaka J,Tomomatsu K,Asano K, Allergic bronchopulmonary aspergillosis in Japan: A nationwide survey. Allergology international : official journal of the Japanese Society of Allergology. 2018 Jan; [PubMed]|
|Vitte J,Ranque S,Carsin A,Gomez C,Romain T,Cassagne C,Gouitaa M,Baravalle-Einaudi M,Bel NS,Reynaud-Gaubert M,Dubus JC,Mège JL,Gaudart J, Multivariate Analysis As a Support for Diagnostic Flowcharts in Allergic Bronchopulmonary Aspergillosis: A Proof-of-Concept Study. Frontiers in immunology. 2017; [PubMed]|
|Bhankhur D,Singla N,Aggarwal D,Chander J, Prevalence of allergic bronchopulmonary aspergillosis among patients with severe bronchial asthma in a tertiary care hospital in Northern India. Indian journal of pathology [PubMed]|
|Sehgal IS,Choudhary H,Dhooria S,Aggarwal AN,Bansal S,Garg M,Behera D,Chakrabarti A,Agarwal R, Prevalence of sensitization to Aspergillus flavus in patients with allergic bronchopulmonary aspergillosis. Medical mycology. 2019 Apr 1; [PubMed]|
|Gago S,Denning DW,Bowyer P, Pathophysiological aspects of Aspergillus colonization in disease. Medical mycology. 2019 Apr 1; [PubMed]|
|Agarwal R,Sehgal IS,Dhooria S,Aggarwal AN, Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis. Expert review of respiratory medicine. 2016 Dec; [PubMed]|
|Shah A,Panjabi C, Allergic Bronchopulmonary Aspergillosis: A Perplexing Clinical Entity. Allergy, asthma [PubMed]|
|Nové-Josserand R,Grard S,Auzou L,Reix P,Murris-Espin M,Brémont F,Mammar B,Mely L,Hubert D,Durieu I,Burgel PR, Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients. Pediatric pulmonology. 2017 Feb; [PubMed]|
|Collins J,Devos G,Hudes G,Rosenstreich D, Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab. Journal of asthma and allergy. 2012; [PubMed]|
|Voskamp AL,Gillman A,Symons K,Sandrini A,Rolland JM,O'Hehir RE,Douglass JA, Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis. The journal of allergy and clinical immunology. In practice. 2015 Mar-Apr; [PubMed]|
|Greenberger PA, Clinical aspects of allergic bronchopulmonary aspergillosis. Frontiers in bioscience : a journal and virtual library. 2003 Jan 1; [PubMed]|
|Jaruratanasirikul S,Sriwiriyajan S, Effect of omeprazole on the pharmacokinetics of itraconazole. European journal of clinical pharmacology. 1998 Apr; [PubMed]|
|Maturu VN,Agarwal R, Acute Invasive Pulmonary Aspergillosis Complicating Allergic Bronchopulmonary Aspergillosis: Case Report and Systematic Review. Mycopathologia. 2015 Oct; [PubMed]|
|Lowes D,Chishimba L,Greaves M,Denning DW, Development of chronic pulmonary aspergillosis in adult asthmatics with ABPA. Respiratory medicine. 2015 Dec; [PubMed]|
|Agarwal R, Allergic bronchopulmonary aspergillosis. Chest. 2009 Mar; [PubMed]|
|Vlahakis NE,Aksamit TR, Diagnosis and treatment of allergic bronchopulmonary aspergillosis. Mayo Clinic proceedings. 2001 Sep; [PubMed]|
|Gibson PG, Allergic bronchopulmonary aspergillosis. Seminars in respiratory and critical care medicine. 2006 Apr; [PubMed]|
|Agarwal R,Khan A,Gupta D,Aggarwal AN,Saxena AK,Chakrabarti A, An alternate method of classifying allergic bronchopulmonary aspergillosis based on high-attenuation mucus. PloS one. 2010 Dec 15; [PubMed]|
|Chishimba L,Niven RM,Cooley J,Denning DW, Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. The Journal of asthma : official journal of the Association for the Care of Asthma. 2012 May; [PubMed]|
|Chauhan B,Santiago L,Kirschmann DA,Hauptfeld V,Knutsen AP,Hutcheson PS,Woulfe SL,Slavin RG,Schwartz HJ,Bellone CJ, The association of HLA-DR alleles and T cell activation with allergic bronchopulmonary aspergillosis. Journal of immunology (Baltimore, Md. : 1950). 1997 Oct 15 [PubMed]|
The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Family Medicine. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.
StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Family Medicine, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Family Medicine, you will already be prepared.
Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Family Medicine. When it is time for the Family Medicine board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Family Medicine.